Biomarkers identification

The LIIC team is very committed to the determination of biomarkers of anti-cancer therapy efficacy. As such, the team belongs to a consortium of private and public partners (Diaclone, Oncodesign, ICMUB, CGFL, CHRU of Besançon, Pharm'image, University of Burgundy, University of Franche Comté ...).